SALT LAKE CITY, Aug. 3, 2020 /PRNewswire/ -- Co-Diagnostics, Inc.
(Nasdaq: CODX), a molecular diagnostics company with a
unique, patented platform for the development of diagnostic tests,
announced today that its partner, Clinical Reference Laboratory
(CRL) has received FDA Emergency Use Authorization for CRL Rapid
Response™, a saliva-based COVID-19 test that can be
self-administered at home, work or any other setting and then
tested using Co-Diagnostics' patented CoPrimer™ technology.
According to CRL's announcement, Co-Diagnostics technology
drives the higher sensitivity and specificity of the
self-administered CRL Rapid Response test. CRL is one of the
largest privately held clinical testing laboratories in the U.S.,
with dedicated facilities in North
America and Europe.
"We believe that CRL's selection of the Co-Diagnostics platform,
and their successful emergency use authorization from the FDA,
speaks volumes about the quality, sensitivity, and specificity of
our CoPrimer primer and probe technology," remarked Dwight Egan, CEO of Co-Diagnostics.
"Co-Diagnostics is pleased to be a part of a testing initiative
with so much potential to help people return to work, school, and
normal life as quickly and safely as possible.
The CE-marked and FDA EUA Co-Diagnostics Logix Smart COVID-19
test is currently available to all clinical laboratories certified
under Clinical Laboratory Improvement Amendments (CLIA), and is
authorized to be used for the diagnosis of SARS-CoV-2, the virus
that causes COVID-19, in the US and many other countries.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a
Utah corporation, is a molecular
diagnostics company that develops, manufactures and markets a new,
state-of-the-art diagnostics technology. The Company's technology
is utilized for tests that are designed using the detection and/or
analysis of nucleic acid molecules (DNA or RNA). The Company also
uses its proprietary technology to design specific tests to locate
genetic markers for use in industries other than infectious disease
and license the use of those tests to specific customers.
Forward-Looking Statements:
This press release
contains forward-looking statements. Forward-looking statements can
be identified by words such as "believes," "expects," "estimates,"
"intends," "may," "plans," "will" and similar expressions, or the
negative of these words. Such forward-looking statements are based
on facts and conditions as they exist at the time such statements
are made and predictions as to future facts and conditions.
Forward-looking statements in this release include statements
regarding the (i) use of funding proceeds, (ii) expansion of
product distribution, (iii) acceleration of initiatives in liquid
biopsy and SNP detection, (iv) use of the Company's liquid biopsy
tests by laboratories, (v) capital resources and runway needed to
advance the Company's products and markets, (vi) increased sales in
the near-term, (vii) flexibility in managing the Company's balance
sheet, (viii) anticipation of business expansion, and (ix) benefits
in research and worldwide accessibility of the CoPrimer technology
and its cost-saving and scientific advantages. Forward-looking
statements are subject to inherent uncertainties, risks and changes
in circumstances. Actual results may differ materially from
those contemplated or anticipated by such forward-looking
statements. Readers of this press release are cautioned not to
place undue reliance on any forward-looking statements. The Company
does not undertake any obligation to update any forward-looking
statement relating to matters discussed in this press release,
except as may be required by applicable securities laws.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/co-diagnostics-inc-technology-to-be-used-in-fda-authorized-self-collected-covid-19-saliva-test-301104409.html
SOURCE Co-Diagnostics